hygroscopicus subsp hygroscopicus
|Synonyms||RAPA, Rapamune, Sirolimus, RPM, Antibiotic AY 22989|
|Description: ||Rapamycin (Sirolimus) is a macrolide compound that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus (Rapamycin) is a potent immunosuppressant. Sirolimus (Rapamycin) possesses both antifungal and antineoplastic properties.|
|CAS number: ||53123-88-9|
|Merck index: ||12, 8288|
|Molecular weight: ||914.2|
|Molecular Formula: ||C51H79NO13|
|Appearance: ||Off-white to slight yellow powder|
|Purity: ||At least 97% by TLC, HPLC|
|λmax:||265, 277, 287|
|Solubility||Rapamycin (Sirolimus) gives clear colorless solution at 50mg/ml DMSO|
|Storage||-20°C. Protect from light and moisture. Hygroscopic.|
|Applications||Medical applications: Rapamycin (Sirolimus) is an immunosuppressant and is used to prevent rejection of kidney and liver transplants. It is also used sometimes in cases of psoriasis, dermatitis.|
Research applications: Rapamycin Sirolimus inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Rapamycin Sirolimus inhibits T-lymphocyte activation / proliferation occuring in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressing agents. Sirolimus also inhibits antibody production.
|Warnings||MAY HARMFUL IF SWALLOWED|
|Related products|| |
| ||For Research use only. Not for Human or Drug use|
GMP/API grade available on request
Rapamycin by Fermentek is not produced from or contains any ingredients from animal origin.
No genetically modified organisms are used.
| ||Ge L, Iakovou I, Cosgrave J, Chieffo A, Montorfano M, Michev I, Airoldi F, Carlino M, Melzi G, Sangiorgi GM, Corvaja N, Colombo A.|
Immediate and mid-term outcomes of Sirolimus (Rapamycin) -eluting stent implantation for chronic total occlusions.
Eur Heart J. 2005 Apr 7
| ||Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, Emre S.|
Sirolimus (Rapamycin) successfully treats post-transplant autoimmune hepatitis.
Am J Transplant. 2005 May;5(5):1085-9
| ||Steiner D, Brunicki N, Bachar-Lustig E, Taylor PA, Blazar BR, Reisner Y.|
Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: Synergism with veto cells and rapamycin. (Sirolimus)
Exp Hematol. 2006 Jun;34(6):802-8
| ||Liu Y.|
Rapamycin and chronic kidney disease: beyond the inhibition of inflammation.
Kidney Int. 2006 Jun;69(11):1925-7.
| ||Okuno S.|
Mammalian target of rapamycin inhibitors in sarcomas.
Curr Opin Oncol. 2006 Jul;18(4):360-2
| ||Liu L, Li F, Cardelli JA, Martin KA, Blenis J, Huang S.|
Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Oncogene. 2006 May 22
| ||Aggarwal D, Fernandez ML, Soliman GA.|
Rapamycin (Sirolimus), an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs.
Metabolism. 2006 Jun;55(6):794-802
| ||Jiang X, Yeung RS.|
Regulation of Microtubule-Dependent Protein Transport by the TSC2/Mammalian Target of Rapamycin Pathway.
Cancer Res. 2006 May 15;66(10):5258-69
| ||Marderosian M, Sharma A, Funk AP, Vartanian R, Masri J, Jo OD, Gera JF.|
Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling.
Oncogene. 2006 May 15
| ||Smolewski P.|
Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Anticancer Drugs. 2006 Jun;17(5):487-94
| ||Webster AC, Lee VW, Chapman JR, Craig JC.|
Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
Transplantation. 2006 May 15;81(9):1234-48
| ||Mercalli A, Sordi V, Ponzoni M, Maffi P, De Taddeo F, Gatti G, Servida P, Bernardi M, Bellio L, Bertuzzi F, Secchi A, Bonifacio E, Piemonti L.|
Rapamycin induces a caspase-independent cell death in human monocytes.
Am J Transplant. 2006 Jun;6(6):1331-41
| ||Kwon YS, Kim JC.|
Inhibition of corneal neovascularization by (Sirolimus) rapamycin .
Exp Mol Med. 2006 Apr 30;38(2):173-9